China's I-Mab Inks $548 Million Immunoncology Pact with Genexine

China's I-Mab Biopharma inked a $548 million agreement with Genexine of South Korea to in-license China rights to Genexine's immunoncology candidate, HyLeukin. I-Mab paid $12 million upfront and is responsible for the remainder in milestones, plus royalties on sales. HyLeukin uses Interleukin-7, a factor in the proliferation and homeostasis of T cells, to create the immunotherapy. Genexine is a prolific dealmaker with China pharmas -- it is a major investor in I-Mab and has forged several deals with Tasly Pharma, also an investor in I-Mab along with C-Bridge Capital. More details....

Stock Symbols: (KOSDAQ, 095700) (SHA: 600535)

Share this with colleagues:

Original Article: China's I-Mab Inks $548 Million Immunoncology Pact with Genexine

More From BioPortfolio on "China's I-Mab Inks $548 Million Immunoncology Pact with Genexine"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications